Moderna, Inc. (MRNA)

186.61
NASDAQ
Prev Close 204.73
Day Low/High 185.39 / 198.82
52 Wk Low/High 117.34 / 497.49
Exchange NASDAQ
Shares Outstanding 405.45B
Market Cap 83.01B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Sorry, but Price Is Not Truth

* I have little conviction in this afternoon's violent rally "Nothing like price to change sentiment." - The Divine Ms. M. I read the same people you follow on Twitter.   I listen to the same people you watch on Fin TV.   They are emboldened (and bu...

Bitten Market, Waning Volume, Virus Thoughts, Jobless Claims Quirk, CPI Watch

Bitten Market, Waning Volume, Virus Thoughts, Jobless Claims Quirk, CPI Watch

Plus, a quick look at earnings report winners and losers from Thursday after the market closed.

Let's Check Up on 2 Immunology-Focused Oncology ETFs

Let's Check Up on 2 Immunology-Focused Oncology ETFs

Here we'll look at the iShares Genomics Immunology and Healthcare ETF and the Cancer Immunotherapy ETF to see how they stack up.

As 2021 IPO Names Tumble, These 2022 Debuts Are Still Drawing Excitement

As 2021 IPO Names Tumble, These 2022 Debuts Are Still Drawing Excitement

Despite the expectation of a tougher sledding for high-flying IPOs, optimism remains for a few key names.

The Surge, Tech Plays, Trading Marvell and MongoDB, Debt Ceiling, Taxes, Omicron

The Surge, Tech Plays, Trading Marvell and MongoDB, Debt Ceiling, Taxes, Omicron

Plus, One must ask themselves... Are Russia and China satisfied with making Ukraine and Taiwan uncomfortable? Do they understand the costs?

Moderna Rated at Cowen

Omicron Panic, Scared Money, A Tech Bright Spot, Fed Talk, My After-Hours Trades

Omicron Panic, Scared Money, A Tech Bright Spot, Fed Talk, My After-Hours Trades

Whether panicked sales over these past few days, especially Wednesday, prove to be either the 'fast' or 'smart' money remains to be seen.

Should Investors Believe in Bounces as Markets Get Choppy?

Should Investors Believe in Bounces as Markets Get Choppy?

Sector selection will remain paramount as pandemic effects continue to permeate.

Faux Rally, Worrisome Words, Omicron Overhang, Microsoft CEO's Stock Sales

Faux Rally, Worrisome Words, Omicron Overhang, Microsoft CEO's Stock Sales

Satya Nadella's decision to sell almost half his stake in Mr. Softee prompts a closer technical look at what may lie ahead for the tech giant's shares.

Omicron Uncertainty Is Causing Fresh Selling

Omicron Uncertainty Is Causing Fresh Selling

The challenge for traders is determining how long the Omicron uncertainty will weigh on the markets.

Why I Am Now Less Bearish

* While I am not bullish, I am less bearish * On a (tactical) trading and even on an investing basis, markets may have overreacted to the Omicron news on Friday * I covered a bunch of shorts on Friday * It might be time to consider being a bit more ...

Omicron, Black Friday, Jobs Week, Cybersecurity, Trading Zscaler

Omicron, Black Friday, Jobs Week, Cybersecurity, Trading Zscaler

I wouldn't expect a lot in the way of economic shutdowns, at least not unless clear evidence presents that people are getting sicker from Omicron.

With the Virus Still in Charge, Pfizer Can Be Flexible: Here's My Plan

With the Virus Still in Charge, Pfizer Can Be Flexible: Here's My Plan

PFE has created what appears to potentially be the most effective antiviral for those already infected.

Variant's Grand Slam, Good Data, Going With the ETF Flow, Eye on Black Friday

Variant's Grand Slam, Good Data, Going With the ETF Flow, Eye on Black Friday

Plus, a thought on how the Fed could approach tapering going forward.

5 Reasons to Bet on Biotech

5 Reasons to Bet on Biotech

Small-cap biotech names are seeing dramatic, widespread declines, creating a liquidation sale for investors.

Hotel California

* What's to like? Very little.. * Though the averages have held up (thank you "Nifty Seven"), a look under the hood reveals a dismal picture of broken stocks and charts  "Last thing I remember, I was Running for the door I had to find the passage ba...

Moderna's Patent Credit, Palantir and ARK, Musk Sells Tesla as EV Stocks Climb

Moderna's Patent Credit, Palantir and ARK, Musk Sells Tesla as EV Stocks Climb

Plus, the intersection of rising inflation and a slowing velocity of money give us reason for pause.

Putting Together an End-of-Year Trading Strategy

Putting Together an End-of-Year Trading Strategy

Let's review areas that are hot, those that are not, and how to position though January.

Options Play of the Week: Dipping Into Dynavax

Options Play of the Week: Dipping Into Dynavax

Knee-jerk reactions to earnings results can create attractive opportunities.

Moderna's Shots Block COVID, but Its Shares Now Have Risky Side Effects

Moderna's Shots Block COVID, but Its Shares Now Have Risky Side Effects

Let's see how far this pharma name could fall, even as it plays a leading role in the battle against the pandemic.

Buying Moderna Now Could Be Akin to Trying to Catch a Falling Knife

Buying Moderna Now Could Be Akin to Trying to Catch a Falling Knife

Here's what traders can do.

Programming Note

I will be out between 9-10 am as I am getting a Moderna booster.

Black Monday Recollections, Bitcoin ETF Launch, Fed Numbers, FDA, Disney's Dip

Black Monday Recollections, Bitcoin ETF Launch, Fed Numbers, FDA, Disney's Dip

While cryptocurrencies are indeed an asset class, and they are divisible, they do not serve as a medium of exchange, and remain unproven as a store of value.

Super Thursday, Filling Gaps, Crypto Regulator Talk, Amazing Alcoa, AMD Love

Super Thursday, Filling Gaps, Crypto Regulator Talk, Amazing Alcoa, AMD Love

Plus, an FDA advisory panel gives a unanimous boost to a Moderna booster shot and Boeing slumps on a negative news report.

These Microcaps Are Making Some Big Noise

These Microcaps Are Making Some Big Noise

I attended the LD Micro Conference in Los Angeles. Here's what I found out.

Where the S&P and Nasdaq Stand, The New Green Team, Trading Southwest and Pfizer

Where the S&P and Nasdaq Stand, The New Green Team, Trading Southwest and Pfizer

With earnings season starting in earnest Wednesday, both indexes have offered investors nothing but lower highs coupled with lower lows since the start of September.

A Series of Fortunate Events, Fiscal Cliff, Powell's Prospects, 4 Trading Notes

A Series of Fortunate Events, Fiscal Cliff, Powell's Prospects, 4 Trading Notes

Market volatility could spike in late November/early December just as liquidity walks away. Keep that in mind.

Dios Mio, Man

Dios Mio, Man   Moderna , a FINTV fave is now -$200/share from its high. Will the bulls take ownership? Rhetorical question, I suppose.